Disorders of glucose metabolism in patients infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 31, Issue 6, 2000, Pages 1467-1475

  Dubé, Michael P ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLUCOSE; PROTEINASE INHIBITOR;

DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; METABOLISM; REVIEW;

ANTI-HIV AGENTS; DIABETES MELLITUS; GLUCOSE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN RESISTANCE;

EID: 0034566874     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317491     Document Type: Article

References (18)

1. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory. Washington, DC: US Food and Drug Administration, 1997.
2. Dubé MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycaemia. Lancet 1997;350:713-4.
3. Dever LL, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Annals of Pharmacotherapy 2000;34:580-4.
4. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
5. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitors. Ann Intern Med 1997;127:948.
6. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
7. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance due to HIV protease inhibitors. AIDS 1998;12:F51-8.
9. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
10. Dubé MP, Aqeel R, Edmondson-Melançon H, et al. Effect of initiating indinavir therapy on glucose metabolism in HIV-infected patients: results of minimal model analysis. Antiviral Therapy 1999;4(Suppl 2):34.
11. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21:209-16.
12. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84:1932-7.
13. Hadigan C, Corcoran C, Stanley T, et al. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000;85:35-41.
14. Shikuma CM, Waslien C, McKeague J, et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999;13:1359-65.
15. Dubé MP, Sprecher D, Henry K, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the Adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.
16. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
17. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-62.
18. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.